Agostino Nicole M, Ali Arjumand, Nair Suresh G, Mosca Paul J
Department of Internal Medicine, Lehigh Valley Hospital and Health Network, 1240 South Cedar Crest Boulevard, Allentown, PA 18103, USA.
Surg Oncol Clin N Am. 2007 Oct;16(4):945-73, xi. doi: 10.1016/j.soc.2007.07.010.
The basis of immunotherapy for melanoma is the existence of melanoma-associated antigens that can be targeted by the immune system. Identification of many of these antigens has enabled investigators to develop a wide array of immunotherapy strategies for the treatment of melanoma. Although several of these strategies have been shown to induce antitumor immune responses in some patients, robust clinical responses have been observed less frequently. With exciting recent advancements in this field, however, there is promise of generating potent immunologic responses and translating them more consistently into durable clinical responses. This article reviews several current approaches to immunotherapy for melanoma and describes the key role that surgeons play in advancing this area of oncology.
黑色素瘤免疫疗法的基础是存在可被免疫系统靶向的黑色素瘤相关抗原。对其中许多抗原的识别使研究人员能够开发出一系列用于治疗黑色素瘤的免疫疗法策略。尽管这些策略中的几种已被证明能在一些患者中诱导抗肿瘤免疫反应,但产生显著临床反应的情况却较少见。然而,随着该领域最近令人兴奋的进展,有望产生强大的免疫反应并将其更持续地转化为持久的临床反应。本文综述了目前几种黑色素瘤免疫疗法方法,并描述了外科医生在推动肿瘤学这一领域发展中所起的关键作用。